Affiliation:
1. Shanghai Tenth People's Hospital
Abstract
Abstract
Ovarian cancer lacks effective therapy. Here, we reported three metastatic ovarian cancer patients administrated with a noval TIL therapy, which was designed glycosylphosphatidylinositol-anchored membrane-bound interleukin-7 (mbIL-7-GPI) to engineer TILs (mbIL-7-TIL) through piggyBac transposon system. In three advanced ovarian cancer patients, infusion of mbIL-7-TILs showed endurable toxicity and prolonged clinical response. After infusion, peripheral mbIL-7-TILs peaked around 5-7 days and then sharply decreased. We found that several clones of engineered T cell and subsequent clones of original T cells underwent significant proliferation in patient 1. Seven months post infusion, mbIL-7-TILs could be detected in tumor liquefactive necrosis of patient 2. These findings indicated that mbIL-7-TILs could efficiently home to tumor lesions and sustainably enhance antitumor immunity in situ, suggesting potent therapeutics to treat advanced OC.
Publisher
Research Square Platform LLC
Reference10 articles.
1. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma;Sarnaik AA;J Clin Oncol,2021
2. Cell therapies in ovarian cancer;Sarivalasis A;Ther Adv Med Oncol,2021
3. Flip the coin: IL-7 and IL-7R in health and disease;Barata JT;Nat Immunol,2019
4. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen;Guo J;J Immunother Cancer,2022
5. A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy;Ren H;Front Immunol,2021